Impact Biomedical Inc（IBO）股票分析IBOImpact Biomedical Inc

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies. It operates in the Healthcare sector.

Impact Biomedical Inc is not a good buy right now due to its current price of 0.4437 and a declining trend in revenue, with total revenue of only 18,000 USD in Q3 2025. Additionally, the company has a concerning 'going concern' qualification in its annual report, which raises significant risks for investors.